Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13865851 | 0.65 | MAPT (0.37) | MAPTMAPK1RAB9APIM1PIM2 | |
| SCHEMBL13865849 | 0.63 | SMN1; SMN2 (0.36) | MAPTMAPK1RAB9APIM1PIM2 | |
| SCHEMBL13865843 | 0.62 | RAB9A (0.51) | MAPTMAPK1RAB9APIM1PIM2 | |
| SCHEMBL13865832 | 0.60 | KDM4E (0.35) | MAPTMAPK1RAB9ACDK4 | |
| SCHEMBL8802391 | 0.57 | MAPT (0.51) | MAPTMAPK1RAB9APIM1PIM2 | |
| SCHEMBL8604288 | 0.57 | MAPT (0.52) | MAPTMAPK1RAB9A | |
| SCHEMBL13865822 | 0.56 | MAPT (0.38) | MAPTMAPK1RAB9ACDK4ATM | |
| SCHEMBL20475325 | 0.55 | RAB9A (0.53) | MAPTMAPK1RAB9AELANE | |
| SCHEMBL31643056 | 0.55 | RAB9A (0.53) | MAPTMAPK1RAB9AELANE | |
| SCHEMBL19655097 | 0.54 | MAPT (0.47) | MAPTRAB9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB7 | MAPT 4476/4885MAPK1 786/4885RAB9A 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.